Navigation Links
JDRF funded research shows promise for prevention, reversal of type 1 diabetes
Date:11/18/2008

New York, NY, November 18, 2008 -- Researchers at the University of California, San Francisco have reported that two common cancer drugs have been used to block and reverse type 1 diabetes in mice. The JDRF-funded study, published in The Proceedings of the National Academy of Sciences, was led by Jeffrey Bluestone, Ph.D., director of the Diabetes Center at UCSF and an expert in the field of autoimmunity.

"The findings suggest that kinase inhibitors successfully used in cancer may provide an important new therapeutic approach for treatment of new onset type 1 diabetes and potentially other autoimmune disorders," said JDRF Director of Immunology Teodora Staeva, Ph.D.

The drugs Imatinib and Sunitnib, sold as Gleevec and Sutent, respectively are used to treat cancer by blocking tyrosine kinases, an enzyme that modify cells' signaling proteins through a simple biochemical change. Kinases trigger cell growth, and it is widely believed that tyrosine kinases are a contributing factor to autoimmune diseases and cancer. The researchers hypothesized that tyrosine kinases may also serve as a trigger to the body's attack on the immune system.

The researchers at the University of California, San Francisco treated non-diabetic mice prone to developing diabetes with imatinib or sunitinib, and found that the drugs prevented the onset of diabetes past the seven-week treatment. Mice that already developed diabetes were treated with the drugs and results concluded that after two months of treatment, 80 percent no longer had diabetes.


'/>"/>

Contact: Jillian Lubarsky
jlubarsky@jdrf.org
212-479-7626
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Page: 1

Related biology news :

1. Mandate for public access to NIH-funded research poised to become law
2. Irritating smells alert special cells, NIH-funded study finds
3. OSU technologies funded for development
4. JDRF-funded clinical trial demonstrates continuous glucose monitoring improves blood sugar control
5. JDRF funded study links hygiene hypothesis to diabetes prevention
6. Research shows skeleton to be endocrine organ
7. Newly created cancer stem cells could aid breast cancer research
8. Dominant cholesterol-metabolism ideas challenged by new research
9. Researchers identify proteins involved in new neurodegenerative syndrome
10. Texas researchers and educators head for Antarctica
11. MGH researchers describe new way to identify, evolve novel enzymes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
Breaking Biology News(10 mins):
(Date:4/28/2017)... USA (PRWEB) , ... April 28, 2017 , ... ... seminar on regulatory compliance requirements for life science products comes to New Orleans, ... structure of the regulatory agencies in Latin America and discuss local cultural nuances ...
(Date:4/28/2017)... ... 28, 2017 , ... Cynvenio Biosystems, Inc. a leader in personalized ... cancer monitoring (NEAT) study in partnership with Allentown, PA-based TME Research . The ... be monitored over two years with Cynvenio’s ClearID Breast Cancer blood test. The study ...
(Date:4/28/2017)... ... April 28, 2017 , ... While things have been quiet ... the company and provide a new outlook for the future. As a continued ... new management with the retirement of Mr. Siegel as CEO. With the new adjustments ...
(Date:4/28/2017)... ... April 28, 2017 , ... KCAS Bioanalytical and Biomarker ... ng/mL lower limit (LLOQ) assay for nicotine and two key metabolites cotinine and ... trace nicotine assay meets additional needs of tobacco industry that need to detect ...
Breaking Biology Technology: